Division of Urology, University of Buenos Aires, Buenos Aires, Argentina.
Prostate Cancer Prostatic Dis. 2009;12(4):369-74. doi: 10.1038/pcan.2009.37. Epub 2009 Sep 1.
This article reports the results of a post hoc analysis of the multicenter, randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) study, which aimed to investigate the effects of dutasteride (0.5 mg), tamsulosin (0.4 mg), and their combination on storage and voiding symptoms in 4844 men aged > or =50 years with moderate-to-severe lower urinary tract symptoms (International Prostate Symptom Score > or =12), prostate volume (PV) > or =30 cm(3) and PSA 1.5-10 ng ml(-1). After 24 months, combination treatment achieved significantly greater mean reductions in both voiding and storage symptoms than either monotherapy, in each of the three baseline PV tertiles (30 to <42, 42 to <58, > or =58 cm(3)). Dutasteride was as effective as tamsulosin for control of storage symptoms, but provided significantly greater relief of voiding symptoms than tamsulosin.
本文报道了多中心、随机、双盲的阿夫唑嗪和坦索罗辛联合治疗(CombAT)研究的事后分析结果,该研究旨在探讨度他雄胺(0.5mg)、坦索罗辛(0.4mg)及其联合应用对 4844 名年龄≥50 岁、中重度下尿路症状(国际前列腺症状评分≥12)、前列腺体积(PV)>30cm³和 PSA 1.5-10ng/ml 的男性的储尿和排尿症状的影响。24 个月后,联合治疗在每个基线 PV 三分位(30-<42、42-<58、≥58cm³)中均显著优于单药治疗,使排尿和储尿症状的平均改善程度更大。度他雄胺在控制储尿症状方面与坦索罗辛一样有效,但在缓解排尿症状方面明显优于坦索罗辛。